# A Study Evaluating the Efficacy and Safety of Pirtobrutinib in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

Source: https://onco.cc/trials/nct06588478/  
OnCo record `nct06588478` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial of Pirtobrutinib in chronic lymphocytic leukaemia, run by Loxo Oncology, Inc., now recruiting.

## Summary

A Study Evaluating the Efficacy and Safety of Pirtobrutinib in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma is a phase 2 interventional study registered as NCT06588478 by Loxo Oncology, Inc., with 249 participants planned, started 2025-01-03 and due to reach its primary completion in 2028-06. Interventions recorded: Pirtobrutinib.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT06588478
- Phase: 2
- Setting: A Phase 2, Open-Label, Randomized Study Evaluating the Efficacy and Safety of 3 Doses of Pirtobrutinib in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Who Previously Received Treatment With a Covalent Bruton Tyrosine Kinase Inhibitor
- Sponsor: Loxo Oncology, Inc.
- Enrolled: 249

## Sources

- ClinicalTrials.gov NCT06588478: https://clinicaltrials.gov/study/NCT06588478

## Connected records

- cancers: [Chronic lymphocytic leukaemia](https://onco.cc/cancers/cll/)
- drugs: [Pirtobrutinib](https://onco.cc/drugs/pirtobrutinib/)
- companies: [Eli Lilly (incl. Loxo)](https://onco.cc/companies/eli-lilly/)

---
JSON: https://onco.cc/api/v1/entities/nct06588478.json